Review Article | Published:

Autism spectrum disorder: insights into convergent mechanisms from transcriptomics

Nature Reviews Geneticsvolume 20pages5163 (2019) | Download Citation


Heredity has a major role in autism spectrum disorder (ASD), yet underlying causal genetic variants have been defined only in a fairly small subset of cases. The enormous genetic heterogeneity associated with ASD emphasizes the importance of identifying convergent pathways and molecular mechanisms that are responsible for this disorder. We review how recent transcriptomic analyses have transformed our understanding of pathway convergence in ASD. In particular, deep RNA sequencing coupled with downstream investigations has revealed that a substantial fraction of autistic brains possess distinct transcriptomic signatures. These signatures are in part a consequence of altered neuronal activity and have a particular impact on pre-mRNA alternative splicing patterns.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Additional information

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



  1. 1.

    Tick, B., Bolton, P., Happe, F., Rutter, M. & Rijsdijk, F. Heritability of autism spectrum disorders: a meta-analysis of twin studies. J. Child Psychol. Psychiatry 57, 585–595 (2016).

  2. 2.

    Colvert, E. et al. Heritability of autism spectrum disorder in a UK population-based twin sample. JAMA Psychiatry 72, 415–423 (2015).

  3. 3.

    Gronborg, T. K., Schendel, D. E. & Parner, E. T. Recurrence of autism spectrum disorders in full- and half-siblings and trends over time: a population-based cohort study. JAMA Pediatr. 167, 947–953 (2013).

  4. 4.

    Gaugler, T. et al. Most genetic risk for autism resides with common variation. Nat. Genet. 46, 881–885 (2014).

  5. 5.

    Sandin, S. et al. The familial risk of autism. JAMA 311, 1770–1777 (2014).

  6. 6.

    Fernandez, B. A. & Scherer, S. W. Syndromic autism spectrum disorders: moving from a clinically defined to a molecularly defined approach. Dialogues Clin. Neurosci. 19, 353–371 (2017).

  7. 7.

    Pinto, D. et al. Convergence of genes and cellular pathways dysregulated in autism spectrum disorders. Am. J. Hum. Genet. 94, 677–694 (2014).

  8. 8.

    Krishnan, A. et al. Genome-wide prediction and functional characterization of the genetic basis of autism spectrum disorder. Nat. Neurosci. 19, 1454–1462 (2016).

  9. 9.

    Wen, Y., Alshikho, M. J. & Herbert, M. R. Pathway network analyses for autism reveal multisystem involvement, major overlaps with other diseases and convergence upon MAPK and calcium signaling. PLOS ONE 11, e0153329 (2016).

  10. 10.

    De Rubeis, S. et al. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature 515, 209–215 (2014).

  11. 11.

    Iossifov, I. et al. The contribution of de novo coding mutations to autism spectrum disorder. Nature 515, 216–221 (2014).

  12. 12.

    Bourgeron, T. From the genetic architecture to synaptic plasticity in autism spectrum disorder. Nat. Rev. Neurosci. 16, 551–563 (2015).

  13. 13.

    Mullins, C., Fishell, G. & Tsien, R. W. Unifying views of autism spectrum disorders: a consideration of autoregulatory feedback loops. Neuron 89, 1131–1156 (2016).

  14. 14.

    de la Torre-Ubieta, L., Won, H., Stein, J. L. & Geschwind, D. H. Advancing the understanding of autism disease mechanisms through genetics. Nat. Med. 22, 345–361 (2016).

  15. 15.

    Kwan, V., Unda, B. K. & Singh, K. K. Wnt signaling networks in autism spectrum disorder and intellectual disability. J. Neurodev. Disord. 8, 45 (2016).

  16. 16.

    Hormozdiari, F., Penn, O., Borenstein, E. & Eichler, E. E. The discovery of integrated gene networks for autism and related disorders. Genome Res. 25, 142–154 (2015).

  17. 17.

    Ebert, D. H. & Greenberg, M. E. Activity-dependent neuronal signalling and autism spectrum disorder. Nature 493, 327–337 (2013).

  18. 18.

    Zhang, L. I. & Poo, M. M. Electrical activity and development of neural circuits. Nat. Neurosci. 4, (Suppl.), 1207–1214 (2001).

  19. 19.

    Nader, K., Schafe, G. E. & Le Doux, J. E. Fear memories require protein synthesis in the amygdala for reconsolidation after retrieval. Nature 406, 722–726 (2000).

  20. 20.

    Salinas, P. C. & Zou, Y. Wnt signaling in neural circuit assembly. Annu. Rev. Neurosci. 31, 339–358 (2008).

  21. 21.

    West, A. E. & Greenberg, M. E. Neuronal activity-regulated gene transcription in synapse development and cognitive function. Cold Spring Harb. Perspect. Biol. 3, a005744 (2011).

  22. 22.

    Maze, I. et al. Critical role of histone turnover in neuronal transcription and plasticity. Neuron 87, 77–94 (2015).

  23. 23.

    Eom, T. et al. NOVA-dependent regulation of cryptic NMD exons controls synaptic protein levels after seizure. eL ife 2, e00178 (2013).

  24. 24.

    Iijima, T. et al. SAM68 regulates neuronal activity-dependent alternative splicing of neurexin-1. Cell 147, 1601–1614 (2011).

  25. 25.

    Xie, J. & Black, D. L. A. CaMK IV responsive RNA element mediates depolarization-induced alternative splicing of ion channels. Nature 410, 936–939 (2001).

  26. 26.

    Mauger, O., Lemoine, F. & Scheiffele, P. Targeted intron retention and excision for rapid gene regulation in response to neuronal activity. Neuron 92, 1266–1278 (2016).

  27. 27.

    Quesnel-Vallieres, M. et al. Misregulation of an activity-dependent splicing network as a common mechanism underlying autism spectrum disorders. Mol. Cell 64, 1023–1034 (2016). A mouse model with SRRM4 levels reduced by half exhibits hallmark features of ASD and thus indicates that SRRM4 reduction and increased microexon skipping can result in ASD phenotypes.

  28. 28.

    Amaral, D. G., Schumann, C. M. & Nordahl, C. W. Neuroanatomy of autism. Trends Neurosci. 31, 137–145 (2008).

  29. 29.

    Purcell, A. E., Jeon, O. H., Zimmerman, A. W., Blue, M. E. & Pevsner, J. Postmortem brain abnormalities of the glutamate neurotransmitter system in autism. Neurology 57, 1618–1628 (2001).

  30. 30.

    Abrahams, B. S. & Geschwind, D. H. Advances in autism genetics: on the threshold of a new neurobiology. Nat. Rev. Genet. 9, 341–355 (2008).

  31. 31.

    Rubenstein, J. L. & Merzenich, M. M. Model of autism: increased ratio of excitation/inhibition in key neural systems. Genes Brain Behav. 2, 255–267 (2003).

  32. 32.

    Garbett, K. et al. Immune transcriptome alterations in the temporal cortex of subjects with autism. Neurobiol. Dis. 30, 303–311 (2008).

  33. 33.

    Parikshak, N. N. et al. Genome-wide changes in lncRNA, splicing, and regional gene expression patterns in autism. Nature 540, 423–427 (2016). Transcriptomic analysis reveals a broader, shared impact of idiopathic ASD on differential expression of long nuclear RNAs, alternative splicing and brain region-specific transcription.

  34. 34.

    Voineagu, I. et al. Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature 474, 380–384 (2011). Transcriptomic analysis of mRNAs suggests the existence of shared molecular hubs that are affected in ASD.

  35. 35.

    Vargas, D. L., Nascimbene, C., Krishnan, C., Zimmerman, A. W. & Pardo, C. A. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann. Neurol. 57, 67–81 (2005).

  36. 36.

    Ashwood, P. et al. Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome. Brain Behav. Immun. 25, 40–45 (2011).

  37. 37.

    Molloy, C. A. et al. Elevated cytokine levels in children with autism spectrum disorder. J. Neuroimmunol. 172, 198–205 (2006).

  38. 38.

    Zimmerman, A. W. et al. Cerebrospinal fluid and serum markers of inflammation in autism. Pediatr. Neurol. 33, 195–201 (2005).

  39. 39.

    Li, X. et al. Elevated immune response in the brain of autistic patients. J. Neuroimmunol. 207, 111–116 (2009).

  40. 40.

    Chez, M. G., Dowling, T., Patel, P. B., Khanna, P. & Kominsky, M. Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic children. Pediatr. Neurol. 36, 361–365 (2007).

  41. 41.

    Atladottir, H. O. et al. Maternal infection requiring hospitalization during pregnancy and autism spectrum disorders. J. Autism Dev. Disord. 40, 1423–1430 (2010).

  42. 42.

    Lee, B. K. et al. Maternal hospitalization with infection during pregnancy and risk of autism spectrum disorders. Brain Behav. Immun. 44, 100–105 (2015).

  43. 43.

    Hornig, M. et al. Prenatal fever and autism risk. Mol. Psychiatry 23, 759–766 (2018).

  44. 44.

    Casanova, M. F. The neuropathology of autism. Brain Pathol. 17, 422–433 (2007).

  45. 45.

    Cellot, G. & Cherubini, E. Functional role of ambient GABA in refining neuronal circuits early in postnatal development. Front. Neural Circuits 7, 136 (2013).

  46. 46.

    Nelson, S. B. & Valakh, V. Excitatory/inhibitory balance and circuit homeostasis in autism spectrum disorders. Neuron 87, 684–698 (2015).

  47. 47.

    Mariani, J. et al. FOXG1-dependent dysregulation of GABA/Glutamate neuron differentiation in autism spectrum disorders. Cell 162, 375–390 (2015). Transcriptomic analysis of brain organoids from patients with ASD with macrocephaly implicates misexpression of FOXG1, which is disrupted in atypical Rett syndrome, as likely causal of observed ASD phenotypes.

  48. 48.

    Kelava, I. & Lancaster, M. A. Dishing out mini-brains: current progress and future prospects in brain organoid research. Dev. Biol. 420, 199–209 (2016).

  49. 49.

    Quadrato, G. et al. Cell diversity and network dynamics in photosensitive human brain organoids. Nature 545, 48–53 (2017).

  50. 50.

    Renner, M. et al. Self-organized developmental patterning and differentiation in cerebral organoids. EMBO J. 36, 1316–1329 (2017).

  51. 51.

    Krichevsky, A. M., King, K. S., Donahue, C. P., Khrapko, K. & Kosik, K. S. A. microRNA array reveals extensive regulation of microRNAs during brain development. RNA 9, 1274–1281 (2003).

  52. 52.

    Sempere, L. F. et al. Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biol. 5, R13 (2004).

  53. 53.

    Kapsimali, M. et al. MicroRNAs show a wide diversity of expression profiles in the developing and mature central nervous system. Genome Biol. 8, R173 (2007).

  54. 54.

    Visvanathan, J., Lee, S., Lee, B., Lee, J. W. & Lee, S. K. The microRNA miR-124 antagonizes the anti-neural REST/SCP1 pathway during embryonic CNS development. Genes Dev. 21, 744–749 (2007).

  55. 55.

    Makeyev, E. V., Zhang, J., Carrasco, M. A. & Maniatis, T. The MicroRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing. Mol. Cell 27, 435–448 (2007).

  56. 56.

    Sanuki, R. et al. miR-124a is required for hippocampal axogenesis and retinal cone survival through Lhx2 suppression. Nat. Neurosci. 14, 1125–1134 (2011).

  57. 57.

    Coolen, M., Katz, S. & Bally-Cuif, L. miR-9: a versatile regulator of neurogenesis. Front. Cell Neurosci. 7, 220 (2013).

  58. 58.

    Fiore, R., Siegel, G. & Schratt, G. MicroRNA function in neuronal development, plasticity and disease. Biochim. Biophys. Acta 1779, 471–478 (2008).

  59. 59.

    Coolen, M. & Bally-Cuif, L. MicroRNAs in brain development and physiology. Curr. Opin. Neurobiol. 19, 461–470 (2009).

  60. 60.

    Fregeac, J., Colleaux, L. & Nguyen, L. S. The emerging roles of MicroRNAs in autism spectrum disorders. Neurosci. Biobehav Rev. 71, 729–738 (2016).

  61. 61.

    Rajman, M. & Schratt, G. MicroRNAs in neural development: from master regulators to fine-tuners. Development 144, 2310–2322 (2017).

  62. 62.

    Sambandan, S. et al. Activity-dependent spatially localized miRNA maturation in neuronal dendrites. Science 355, 634–637 (2017). Visualization of single-synapse stimulation-dependent local maturation of miRNA that then contributes to spatially restricted reduction in the translation of a target mRNA.

  63. 63.

    Kozomara, A. & Griffiths-Jones, S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 42, D68–D73 (2014).

  64. 64.

    Abu-Elneel, K. et al. Heterogeneous dysregulation of microRNAs across the autism spectrum. Neurogenetics 9, 153–161 (2008).

  65. 65.

    Zhang, W. et al. MiRNA-128 regulates the proliferation and neurogenesis of neural precursors by targeting PCM1 in the developing cortex. eLife 5, e11324 (2016).

  66. 66.

    Ander, B. P., Barger, N., Stamova, B., Sharp, F. R. & Schumann, C. M. Atypical miRNA expression in temporal cortex associated with dysregulation of immune, cell cycle, and other pathways in autism spectrum disorders. Mol. Autism 6, 37 (2015).

  67. 67.

    Stamova, B., Ander, B. P., Barger, N., Sharp, F. R. & Schumann, C. M. Specific regional and age-related small noncoding RNA expression patterns within superior temporal gyrus of typical human brains are less distinct in autism brains. J. Child Neurol. 30, 1930–1946 (2015).

  68. 68.

    Wu, Y. E., Parikshak, N. N., Belgard, T. G. & Geschwind, D. H. Genome-wide, integrative analysis implicates microRNA dysregulation in autism spectrum disorder. Nat. Neurosci. 19, 1463–1476 (2016). Transcriptomic analysis highlights possible involvement of miRNAs in idiopathic ASD.

  69. 69.

    Rogelj, B. Brain-specific small nucleolar RNAs. J. Mol. Neurosci. 28, 103–109 (2006).

  70. 70.

    Vitali, P., Royo, H., Marty, V., Bortolin-Cavaille, M. L. & Cavaille, J. Long nuclear-retained non-coding RNAs and allele-specific higher-order chromatin organization at imprinted snoRNA gene arrays. J. Cell Sci. 123, 70–83 (2010).

  71. 71.

    Cavaille, J. Box C/D small nucleolar RNA genes and the Prader-Willi syndrome: a complex interplay. Wiley Interdiscip. Rev. RNA 8, e1417 (2017).

  72. 72.

    Wright, C. et al. Altered expression of histamine signaling genes in autism spectrum disorder. Transl Psychiatry 7, e1126 (2017).

  73. 73.

    Qin, Y. et al. SNORA74B gene silencing inhibits gallbladder cancer cells by inducing PHLPP and suppressing Akt/mTOR signaling. Oncotarget 8, 19980–19996 (2017).

  74. 74.

    Kelleher, R. J. 3rd & Bear, M. F. The autistic neuron: troubled translation? Cell 135, 401–406 (2008).

  75. 75.

    Geisler, S. & Coller, J. RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. Nat. Rev. Mol. Cell Biol. 14, 699–712 (2013).

  76. 76.

    Derrien, T. et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res. 22, 1775–1789 (2012).

  77. 77.

    Necsulea, A. et al. The evolution of lncRNA repertoires and expression patterns in tetrapods. Nature 505, 635–640 (2014).

  78. 78.

    Ng, S. Y., Johnson, R. & Stanton, L. W. Human long non-coding RNAs promote pluripotency and neuronal differentiation by association with chromatin modifiers and transcription factors. EMBO J. 31, 522–533 (2012).

  79. 79.

    Ramos, A. D. et al. The long noncoding RNA Pnky regulates neuronal differentiation of embryonic and postnatal neural stem cells. Cell Stem Cell 16, 439–447 (2015).

  80. 80.

    Ziats, M. N. & Rennert, O. M. Aberrant expression of long noncoding RNAs in autistic brain. J. Mol. Neurosci. 49, 589–593 (2013).

  81. 81.

    Wong, R. W. & Guillaud, L. The role of epidermal growth factor and its receptors in mammalian CNS. Cytokine Growth Factor Rev. 15, 147–156 (2004).

  82. 82.

    Turner, C. A., Akil, H., Watson, S. J. & Evans, S. J. The fibroblast growth factor system and mood disorders. Biol. Psychiatry 59, 1128–1135 (2006).

  83. 83.

    Kerin, T. et al. A noncoding RNA antisense to moesin at 5p14.1 in autism. Sci. Transl Med. 4, 128ra40 (2012).

  84. 84.

    Velmeshev, D., Magistri, M. & Faghihi, M. A. Expression of non-protein-coding antisense RNAs in genomic regions related to autism spectrum disorders. Mol. Autism 4, 32 (2013).

  85. 85.

    Gudenas, B. L., Srivastava, A. K. & Wang, L. Integrative genomic analyses for identification and prioritization of long non-coding RNAs associated with autism. PLOS ONE 12, e0178532 (2017).

  86. 86.

    Pan, Q., Shai, O., Lee, L. J., Frey, B. J. & Blencowe, B. J. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat. Genet. 40, 1413–1415 (2008).

  87. 87.

    Wang, E. T. et al. Alternative isoform regulation in human tissue transcriptomes. Nature 456, 470–476 (2008).

  88. 88.

    Raj, B. & Blencowe, B. J. Alternative splicing in the mammalian nervous system: recent insights into mechanisms and functional roles. Neuron 87, 14–27 (2015).

  89. 89.

    Norris, A. D. & Calarco, J. A. Emerging roles of alternative pre-mRNA splicing regulation in neuronal development and function. Front. Neurosci. 6, 122 (2012).

  90. 90.

    Vuong, C. K., Black, D. L. & Zheng, S. The neurogenetics of alternative splicing. Nat. Rev. Neurosci. 17, 265–281 (2016).

  91. 91.

    Darnell, R. B. RNA protein interaction in neurons. Annu. Rev. Neurosci. 36, 243–270 (2013).

  92. 92.

    Zhou, Y. D., F. & Mao, Y. Control of CNS functions by RNA-binding proteins in neurological diseases. Curr. Pharmacol. Rep. 4, 301–313 (2018).

  93. 93.

    Didiot, M. C. et al. The G-quartet containing FMRP binding site in FMR1 mRNA is a potent exonic splicing enhancer. Nucleic Acids Res. 36, 4902–4912 (2008).

  94. 94.

    Zhou, L. T. et al. A novel role of fragile X mental retardation protein in pre-mRNA alternative splicing through RNA-binding protein 14. Neuroscience 349, 64–75 (2017).

  95. 95.

    Jeffery, L. & Nakielny, S. Components of the DNA methylation system of chromatin control are RNA-binding proteins. J. Biol. Chem. 279, 49479–49487 (2004).

  96. 96.

    Young, J. I. et al. Regulation of RNA splicing by the methylation-dependent transcriptional repressor methyl-CpG binding protein 2. Proc. Natl Acad. Sci. USA 102, 17551–17558 (2005).

  97. 97.

    Cheng, T. L. et al. Regulation of mRNA splicing by MeCP2 via epigenetic modifications in the brain. Sci. Rep. 7, 42790 (2017).

  98. 98.

    Osenberg, S. et al. Activity-dependent aberrations in gene expression and alternative splicing in a mouse model of Rett syndrome. Proc. Natl Acad. Sci. USA 115, E5363–E5372 (2018).

  99. 99.

    Fogel, B. L. et al. RBFOX1 regulates both splicing and transcriptional networks in human neuronal development. Hum. Mol. Genet. 21, 4171–4186 (2012).

  100. 100.

    Lovci, M. T. et al. Rbfox proteins regulate alternative mRNA splicing through evolutionarily conserved RNA bridges. Nat. Struct. Mol. Biol. 20, 1434–1442 (2013).

  101. 101.

    Weyn-Vanhentenryck, S. M. et al. HITS-CLIP and integrative modeling define the Rbfox splicing-regulatory network linked to brain development and autism. Cell Rep. 6, 1139–1152 (2014). Analysis of RBFOX-bound RNAs reveals an enrichment of RBFOX-dependent alternative spicing events in ASD-associated or ASD-causing genes.

  102. 102.

    Martin, C. L. et al. Cytogenetic and molecular characterization of A2BP1/FOX1 as a candidate gene for autism. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B, 869–876 (2007).

  103. 103.

    Sebat, J. et al. Strong association of de novo copy number mutations with autism. Science 316, 445–449 (2007). A systematic analysis of copy number variants uncovers their association with ASD.

  104. 104.

    Davis, L. K. et al. Rare inherited A2BP1 deletion in a proband with autism and developmental hemiparesis. Am. J. Med. Genet. A 158A, 1654–1661 (2012).

  105. 105.

    Lee, J. A. et al. Cytoplasmic Rbfox1 regulates the expression of synaptic and autism-related genes. Neuron 89, 113–128 (2016). Transcriptomic analysis reveals differential binding of RBFOX1 to distinct sets of cytoplasmic and nuclear mRNAs. Cytoplasmic RBFOX1 target mRNAs are enriched in ASD-associated genes.

  106. 106.

    Ray, D. et al. A compendium of RNA-binding motifs for decoding gene regulation. Nature 499, 172–177 (2013).

  107. 107.

    Gehman, L. T. et al. The splicing regulator Rbfox1 (A2BP1) controls neuronal excitation in the mammalian brain. Nat. Genet. 43, 706–711 (2011).

  108. 108.

    Jeste, S. S. & Geschwind, D. H. Disentangling the heterogeneity of autism spectrum disorder through genetic findings. Nat. Rev. Neurol. 10, 74–81 (2014).

  109. 109.

    Irimia, M. et al. A highly conserved program of neuronal microexons is misregulated in autistic brains. Cell 159, 1511–1523 (2014). Transcriptomic analysis defines a microexon splicing programme regulated by the SRRM4 alternative splicing factor. SRRM4 is downregulated and microexons are preferentially skipped in over one-third of post-mortem brain samples from idiopathic ASD cases analysed.

  110. 110.

    Pan, Q. et al. Revealing global regulatory features of mammalian alternative splicing using a quantitative microarray platform. Mol. Cell 16, 929–941 (2004).

  111. 111.

    Li, Y. I., Sanchez-Pulido, L., Haerty, W. & Ponting, C. P. RBFOX and PTBP1 proteins regulate the alternative splicing of micro-exons in human brain transcripts. Genome Res. 25, 1–13 (2015).

  112. 112.

    Quesnel-Vallieres, M., Irimia, M., Cordes, S. P. & Blencowe, B. J. Essential roles for the splicing regulator nSR100/SRRM4 during nervous system development. Genes Dev. 29, 746–759 (2015).

  113. 113.

    Ataman, B. et al. Evolution of Osteocrin as an activity-regulated factor in the primate brain. Nature 539, 242–247 (2016).

  114. 114.

    Ustianenko, D., Weyn-Vanhentenryck, S. M. & Zhang, C. Microexons: discovery, regulation, and function. Wiley Interdiscip. Rev. RNA 8, e1418 (2017).

  115. 115.

    Rusconi, F. et al. LSD1 neurospecific alternative splicing controls neuronal excitability in mouse models of epilepsy. Cerebral Cortex 25, 2729–2740 (2014).

  116. 116.

    Fuccillo, M. V. Striatal circuits as a common node for autism pathophysiology. Front. Neurosci. 10, 27 (2016).

  117. 117.

    Cohen, S. et al. Genome-wide activity-dependent MeCP2 phosphorylation regulates nervous system development and function. Neuron 72, 72–85 (2011).

  118. 118.

    Suhl, J. A. et al. A 3ʹ untranslated region variant in FMR1 eliminates neuronal activity-dependent translation of FMRP by disrupting binding of the RNA-binding protein HuR. Proc. Natl Acad. Sci. USA 112, E6553–E6561 (2015).

  119. 119.

    Abrahams, B. S. et al. SFARI gene 2.0: a community-driven knowledgebase for the autism spectrum disorders (ASDs). Mol. Autism 4, 36 (2013).

  120. 120.

    Takata, A., Ionita-Laza, I., Gogos, J. A., Xu, B. & Karayiorgou, M. De novo synonymous mutations in regulatory elements contribute to the genetic etiology of autism and schizophrenia. Neuron 89, 940–947 (2016).

  121. 121.

    Corominas, R. et al. Protein interaction network of alternatively spliced isoforms from brain links genetic risk factors for autism. Nat. Commun. 5, 3650 (2014).

  122. 122.

    Li, Y. I. et al. RNA splicing is a primary link between genetic variation and disease. Science 352, 600–604 (2016).

  123. 123.

    Takata, A., Matsumoto, N. & Kato, T. Genome-wide identification of splicing QTLs in the human brain and their enrichment among schizophrenia-associated loci. Nat. Commun. 8, 14519 (2017).

  124. 124.

    Gandal, M. J. et al. Shared molecular neuropathology across major psychiatric disorders parallels polygenic overlap. Science 359, 693–697 (2018).

  125. 125.

    Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 381, 1371–1379 (2013).

  126. 126.

    Kim, Y. S. et al. Prevalence of autism spectrum disorders in a total population sample. Am. J. Psychiatry 168, 904–912 (2011).

  127. 127.

    Jeong, H. & Tiwari, V. K. Exploring the complexity of cortical development using single-cell transcriptomics. Front. Neurosci. 12, 31 (2018).

  128. 128.

    Wang, P., Zhao, D., Lachman, H. M. & Zheng, D. Enriched expression of genes associated with autism spectrum disorders in human inhibitory neurons. Transl Psychiatry 8, 13 (2018).

  129. 129.

    Reddy, K. S. Cytogenetic abnormalities and fragile-X syndrome in autism spectrum disorder. BMC Med. Genet. 6, 3 (2005).

  130. 130.

    Fernandez, E., Rajan, N. & Bagni, C. The FMRP regulon: from targets to disease convergence. Front. Neurosci. 7, 191 (2013).

  131. 131.

    The Dutch-Belgian Fragile X Consortium. Fmr1 knockout mice: a model to study fragile X mental retardation. Cell 78, 23–33 (1994).

  132. 132.

    Halevy, T., Czech, C. & Benvenisty, N. Molecular mechanisms regulating the defects in fragile X syndrome neurons derived from human pluripotent stem cells. Stem Cell Rep. 4, 37–46 (2015).

  133. 133.

    Amir, R. E. et al. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 23, 185–188 (1999).

  134. 134.

    Richards, C., Jones, C., Groves, L., Moss, J. & Oliver, C. Prevalence of autism spectrum disorder phenomenology in genetic disorders: a systematic review and meta-analysis. Lancet Psychiatry 2, 909–916 (2015).

  135. 135.

    Lyst, M. J. et al. Rett syndrome mutations abolish the interaction of MeCP2 with the NCoR/SMRT co-repressor. Nat. Neurosci. 16, 898–902 (2013).

  136. 136.

    Kyle, S. M., Saha, P. K., Brown, H. M., Chan, L. C. & Justice, M. J. MeCP2 co-ordinates liver lipid metabolism with the NCoR1/HDAC3 corepressor complex. Hum. Mol. Genet. 25, 3029–3041 (2016).

  137. 137.

    Kyle, S. M., Vashi, N. & Justice, M. J. Rett syndrome: a neurological disorder with metabolic components. Open Biol. 8, 170216 (2018).

  138. 138.

    Lin, P. et al. Transcriptome analysis of human brain tissue identifies reduced expression of complement complex C1Q genes in Rett syndrome. BMC Genomics 17, 427 (2016).

  139. 139.

    Gogliotti, R. G. et al. Total RNA sequencing of Rett syndrome autopsy samples identifies the M4 muscarinic receptor as a novel therapeutic target. J. Pharmacol. Exp. Ther. 365, 291–300 (2018).

  140. 140.

    Bennett, J. A., Germani, T., Haqq, A. M. & Zwaigenbaum, L. Autism spectrum disorder in Prader-Willi syndrome: a systematic review. Am. J. Med. Genet. A 167A, 2936–2944 (2015).

  141. 141.

    Depienne, C. et al. Screening for genomic rearrangements and methylation abnormalities of the 15q11-q13 region in autism spectrum disorders. Biol. Psychiatry 66, 349–359 (2009).

  142. 142.

    Buiting, K. Prader-Willi syndrome and Angelman syndrome. Am. J. Med. Genet. C Semin. Med. Genet. 154C, 365–376 (2010).

  143. 143.

    Ding, F. et al. SnoRNA Snord116 (Pwcr1/MBII-85) deletion causes growth deficiency and hyperphagia in mice. PLOS ONE 3, e1709 (2008).

  144. 144.

    Qi, Y. et al. Snord116 is critical in the regulation of food intake and body weight. Sci. Rep. 6, 18614 (2016).

  145. 145.

    Dindot, S. V., Antalffy, B. A., Bhattacharjee, M. B. & Beaudet, A. L. The Angelman syndrome ubiquitin ligase localizes to the synapse and nucleus, and maternal deficiency results in abnormal dendritic spine morphology. Hum. Mol. Genet. 17, 111–118 (2008).

  146. 146.

    Ellegood, J. et al. Neuroanatomical phenotypes are consistent with autism-like behavioral phenotypes in the 15q11-13 duplication mouse model. Autism Res. 8, 545–555 (2015).

  147. 147.

    Nakatani, J. et al. Abnormal behavior in a chromosome-engineered mouse model for human 15q11-13 duplication seen in autism. Cell 137, 1235–1246 (2009).

  148. 148.

    Bochukova, E. G. et al. A transcriptomic signature of the hypothalamic response to fasting and BDNF deficiency in Prader-Willi syndrome. Cell Rep. 22, 3401–3408 (2018).

  149. 149.

    Germain, N. D. et al. Gene expression analysis of human induced pluripotent stem cell-derived neurons carrying copy number variants of chromosome 15q11-q13.1. Mol. Autism 5, 44 (2014).

  150. 150.

    Chow, M. L. et al. Age-dependent brain gene expression and copy number anomalies in autism suggest distinct pathological processes at young versus mature ages. PLOS Genet. 8, e1002592 (2012).

  151. 151.

    Gupta, S. et al. Transcriptome analysis reveals dysregulation of innate immune response genes and neuronal activity-dependent genes in autism. Nat. Commun. 5, 5748 (2014).

Download references


This work was supported by Canadian Institutes of Health Research (CIHR) grants to S.P.C. and B.J.B. and by a Simons Foundation grant to B.J.B. M.Q.-V. was supported by a CIHR scholarship and an Ontario Graduate Scholarship. B.J.B. holds the University of Toronto Banbury Chair in Medical Research.

Reviewer information

Nature Reviews Genetics thanks G. Konopka and the other, anonymous reviewer(s) for their contribution to the peer review of this work.

Author information

Author notes

    • Mathieu Quesnel-Vallières

    Present address: Department of Biochemistry and Biophysics and Department of Genetics, University of Pennsylvania, Philadelphia, PA, USA

    • Robert J. Weatheritt

    Present address: EMBL Australia, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia


  1. Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada

    • Mathieu Quesnel-Vallières
    • , Sabine P. Cordes
    •  & Benjamin J. Blencowe
  2. Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada

    • Mathieu Quesnel-Vallières
    •  & Sabine P. Cordes
  3. Donnelly Centre, University of Toronto, Toronto, Ontario, Canada

    • Mathieu Quesnel-Vallières
    • , Robert J. Weatheritt
    •  & Benjamin J. Blencowe


  1. Search for Mathieu Quesnel-Vallières in:

  2. Search for Robert J. Weatheritt in:

  3. Search for Sabine P. Cordes in:

  4. Search for Benjamin J. Blencowe in:


All authors researched data for the article, provided substantial contribution to discussions of the content and reviewed or edited the manuscript before submission. M.Q.-V., S.P.C. and B.J.B. wrote the article.

Competing interests

The authors declare no competing interests.

Corresponding authors

Correspondence to Mathieu Quesnel-Vallières or Sabine P. Cordes or Benjamin J. Blencowe.


Glutamate signalling

Molecular pathway that includes the excitatory neurotransmitter glutamate and its synaptic receptors; largely responsible for driving neuronal activity.

Excitatory-to-inhibitory imbalance

Change in the ratio between excitatory (primarily glutamate) and inhibitory (primarily GABA) synaptic transmission that regulates normal brain activity and behaviour.

Glutamatergic neurons

Glutamate-expressing neurons that potentiate neuronal activity.

GABAergic neurons

GABA-expressing neurons that act as inhibitors of neuronal activity.


Process during which neural stem cells proliferate and differentiate into glial cells and neurons to generate the cortex during brain development.


GABAergic interneurons are a type of inhibitory neuron that filters neuronal activity and maintains the excitatory-to-inhibitory balance.

Cerebral organoids

Tissues grown in vitro from embryonic stem cells or induced pluripotent stem cells under conditions that promote the generation of differentiated, cortex-like structures (including neurons) to model brain development.

Cortical layering

Anatomical distribution of neurons into six molecularly distinct layers in the cortex during brain development; this layering is conserved in mammals.

Cassette exons

Exons that can be skipped or included in mRNA transcripts through alternative splicing.

Splicing quantitative trait loci

Genomic regions that are associated with variations in splicing patterns.

About this article

Publication history


Issue Date